Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research (DENEM)

28 agosto 2026 aggiornato da: Liverpool School of Tropical Medicine

Dengue Evaluation of Multi-State Models (DENEM Study): A Prospective Observational Study of Patients Hospitalised With Dengue Vascular Leak in Nha Trang, Vietnam, to Develop Novel Statistical Methodology

The goal of this observational study is to investigate the natural history of dengue in hospitalised patients in Vietnam, to better understand the disease process, and utilise the data to improve future clinical trials. The main questions it aims to answer are:

In participants hospitalised with dengue in Vietnam:

  1. How does dengue illness change over time, particularly the development and recovery of vascular leak (where blood vessels leak)?
  2. Can a new statistical approaches describe dengue illness accurately and be suitable for use in future clinical trials?
  3. Which blood biomarkers are associated with worsening or improving dengue illness, and what do they tell us about how severe dengue develops? Could these blood biomarkers act as reliable indicators of disease severity and recovery, making them useful outcome measures in future dengue treatment trials?
  4. How accurately do simplified diagnostic tests identify dengue compared with laboratory reference methods, and are they suitable for use in research and clinical settings in low- and middle-income countries?

Participants will be observed without any intervention throughout their hospitalisation. Participants will be be asked to provide informed consent for:

  • Recording of their routine clinical data
  • Regular blood tests
  • Regular ultrasound scans
  • A follow up appointment.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

Dengue is a life-threatening infection caused by a virus, spread between humans by the bite of mosquitoes. It is present throughout the tropics, including in Vietnam, where cases have dramatically increased in recent years. Dengue causes severe illness predominantly through vascular leak, where patients' blood vessels break down, becoming leaky, leading to fluid from the vessels moving into tissues and organs such as the lungs.

However, it is still not fully understand how the virus causes vascular leak, or in which patients it is most likely to occur in. There are no licensed treatments for vascular leak. This is because the mechanism of vascular leak is incompletely understood, making therapeutic targeting difficult. Additionally, when drugs are trialled, many trials have been poorly designed and not included enough patients.

To answer our research questions, the investigators will recruit 142 patients admitted to hospital with dengue in Nha Trang, Vietnam who have dengue vascular leak. If they are happy to enter the study, data will be recorded that is already being collected as part of their hospital admission; this will include clinical data (such as blood pressure, pulse and treatments given) and the results of their blood tests. Investigators will also run tests beyond what they would normally have in hospital; this will include the results of regular ultrasound scans and biomarker blood tests (small molecules that can be detected in their blood in response to stress and vascular leak). Most patients have blood tests daily in hospital, and clinicians will aim to take the extra tubes of blood required at the same time, to minimise the number of extra procedures requested from participants.

Investigators will put this data it into a statistical model of dengue vascular leak they have been developing, called a multi-state model. These models have previously been used in other areas of medicine, but this would be their first application in dengue and infectious diseases research. Multi-state models aim to track how patients move through different stages of illness over time. Models such as this make better use of all the information collected during a patient's illness. Rather than only looking at a single outcome, such as whether a patient had recovered by a certain day, or how long recovery took, they track how patients move through different stages of dengue over time and how long they spend in each stage. This may give a more complete picture of how treatments affect the course of illness. If successful, it could improve how future dengue clinical trials are designed, helping researchers detect whether new treatments work more quickly and with fewer volunteers.

Investigators will also use data and samples collected from this study to explore why vascular leak occurs and evaluate new ways of diagnosing dengue, particularly in low-resource settings. To achieve this, investigators will need to compare patients who have dengue to people who have not got dengue, looking for differences. As such 93 people who do not have dengue (called "control" participants) will be recruited. Some will have a fever from another cause, and others will be healthy volunteers. Comparing these control populations with patients who have dengue helps us understand which findings are specific to dengue and how accurate new dengue tests are. People in these groups will only have a single small blood sample taken and will not receive any treatment or need follow-up visits.

Overall, this study aims to support the development of better treatments and more efficient clinical trials for dengue.

Tipo di studio

Osservativo

Iscrizione (Stimato)

235

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Nha Trang, Vietnam
        • Nagasaki University Vietnam Research Station, Nha Trang
        • Contatto:
        • Investigatore principale:
          • Lay Myint Yoshida, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients presenting to Khánh Hòa Hospital of Tropical Diseases, Nha Trang, Vietnam.

Descrizione

Inclusion Criteria (hospitalised cohort):

  • Meet the 2009 WHO criteria for dengue with warning signs or severe dengue AND
  • Are being admitted as an inpatient AND
  • Have documented standard-of-care laboratory confirmation of dengue (defined as either positive by molecular assay (e.g. reverse transcription polymerase chain reaction) OR positive by antigen testing (non-structural protein-1) OR positive Immunoglobulin M (IgM) combined with clinical diagnosis of dengue by attending physician. AND
  • Were born in Vietnam (only for platelet phenomics substudy)

Inclusion Criteria (diagnostic control cohort):

  • Have a documented fever at assessment AND
  • Have a documented negative standard-of-care dengue test, with no clinical diagnosis of dengue AND
  • Were born in Vietnam (only for platelet phenomics substudy)

Inclusion Criteria (platelet control cohort):

  • Vietnamese-born adults ≥16 years of age with no history of febrile illness in the preceding 14 days.

Exclusion Criteria:

  • Receiving an experimental dengue treatment during their illness.
  • Inability to provide written, informed consent AND no legal guardian able to provide written, informed consent in the event of incapacity.
  • Clinician-determined unsuitability for recruitment.

Exclusion Criteria (platelet substudy only):

  • Any non-steroidal anti-inflammatory, antiplatelet or anticoagulant medication received in preceding 7 days.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Hospitalised Cohort
Patients hospitalised with dengue with warning signs or severe dengue
Diagnostic Control Cohort
Patients with non-dengue febrile illness
Platelet Control Cohort
Healthy Vietnamese volunteers

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Degree of vascular leak
Lasso di tempo: From enrollment until day 10 of illness, or discharge
Presence and severity of vascular leak (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - composite of change of haematocrit from baseline, presence of ascites/pleural effusion by point of care ultrasound and presence of respiratory/cardiovascular compromise.
From enrollment until day 10 of illness, or discharge

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Multi-state model evaluation - precision
Lasso di tempo: Assessed at 3 days and 5 days post admission
Confidence in model parameters: 95% confidence interval width around 3- and 5-day probabilities of all state transition pairs (probability with 95% confidence interval)
Assessed at 3 days and 5 days post admission
Multi-state model evaluation: model fit
Lasso di tempo: From enrollment until day 10 of illness or discharge
Goodness of fit of model compared to observed data, as assessed by Akaike information criteria (AIC) values, Bayesian information criteria (BIC) values and Likelihood-ratio test (p-value)
From enrollment until day 10 of illness or discharge
Viral dynamics
Lasso di tempo: From enrollment until day 10 of illness, or discharge
Dengue viral load by reverse-transcriptase polymerase chain reaction (copies per microlitre)
From enrollment until day 10 of illness, or discharge
Degree of thrombocytopenia
Lasso di tempo: From enrollment until day 10 of illness or discharge
Presence and severirty of thrombocytopenia (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - measured by platelet count (10^9/L)
From enrollment until day 10 of illness or discharge
Degree of bleeding
Lasso di tempo: From enrollment until day 10 of illness or discharge
Presence and severirty of bleeding (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - composite score measured by presence/absence of clinical bleeding, requirement for local intervention, cardiovascular compromise, requirement for blood transfusion.
From enrollment until day 10 of illness or discharge
Modified sequenetial organ failure score (mSOFA)
Lasso di tempo: From enrollment until day 10 of illness or discharge
mSOFA score composite score (0-24) with 6 systems assessed, each component contributing 0-4 points to the overal score. Systems assessed: respiratory system (peripheral saturations of oxygen/fraction inspired oxygen, mmHg), Coagulation (platelet count / microlitre), Liver function (Bilirubin, mg/dl), Cardiovascular system (mean arterial pressure / pulse pressure, mmHg), Central nervous system (glasgow coma score), renal function (creatinin, mg/dL or urine output, mL/day)
From enrollment until day 10 of illness or discharge
Volume of Intravenous Fluid Received in 24 hours
Lasso di tempo: From enrollment until day 10 of illness or discharge
Fluid type and volume (mL)
From enrollment until day 10 of illness or discharge
Dengue Clinical Severity
Lasso di tempo: From enrollment until day 10 of illness or discharge
Dengue clinical severity classification per WHO 2009 criteria (dengue without warning signs, dengue with warning signs, severe dengue)
From enrollment until day 10 of illness or discharge
Concentration of a panel of plasma biomarkers of endothelial dysfunction, inflammation and platelet dysfunction.
Lasso di tempo: From enrollment until day 10 of illness, or discharge
Longitudinal measurement of biomarkers such as Syndecan-1, Angiopoietin 1/2, VCAM-1, CRP, Ferritin, platelet function assay, platelet-leucocyte aggregate assay, platelet receptor panel
From enrollment until day 10 of illness, or discharge
Performance of plasma biomarkers of dengue vascular leak as robust secondary endpoints in future dengue interventional trials.
Lasso di tempo: From enrollment until day 10 of illness or discharge
Correlation of biomarker values with clinical and model outcomes
From enrollment until day 10 of illness or discharge
Performance of dengue diagnostic platforms, for use in participant screening in low- and middle-income countries.
Lasso di tempo: At enrollment
Diagnostic accuracy of novel LAMP assay compared to reference standard and RDT: sensitivity, specificity and predictive values of diagnostic platforms against RT-PCR as reference and RDTs as standard of care.
At enrollment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 aprile 2028

Completamento dello studio (Stimato)

1 aprile 2028

Date di iscrizione allo studio

Primo inviato

5 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 agosto 2026

Primo Inserito (Effettivo)

2 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Anonymised study results will be made publicly available through scientific publications and, where appropriate, data repositories. Requests from bona fide researchers for access to de-identified participant-level data will be considered on a case-by-case basis, subject to applicable ethical approvals, participant consent, and local and institutional policies.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi